Ekaterina S. Manuilova

Penzberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Blood-based pre-screening in the SKYLINE secondary prevention Ph3 gantenerumab study.

Blood-based pre-screening in the SKYLINE secondary prevention Ph3 gantenerumab study.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: June 04, 2025

Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSF.

Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSF.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: April 29, 2025

Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer's disease assessment: findings from the Apollo study.

Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer's disease assessment: findings from the Apollo study.

Journal: Clinical chemistry and laboratory medicine

Published: December 19, 2024

Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.

Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.

Journal: The journal of prevention of Alzheimer's disease

Published: July 16, 2022

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease.

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease.

Journal: Clinical chemistry and laboratory medicine

Published: May 27, 2022

Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening.

Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: May 04, 2022

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: February 27, 2022

Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation.

Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation.

Journal: Alzheimer's research & therapy

Published: February 02, 2022

Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF.

Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: October 16, 2020

First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays.

First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: February 27, 2020

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.

Journal: Alzheimer's research & therapy

Published: October 11, 2019

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Journal: Clinical biochemistry

Published: May 10, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026